Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05696080 · ClinicalTrials.gov registry record · Phase 3
Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008)
A Phase 3 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 3
- Development phase
- 518
- Enrollment target
NCT05696080 is a Phase 3 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 518 participants.
The verdict
NCT05696080, a Phase 3 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 518 participants
- Enrollment target
Study Summary
The primary objectives of this study are to evaluate the safety and tolerability of the pneumococcal 21 valent conjugate vaccine (V116), and to evaluate the serotype-specific opsonophagocytic activity (OPA) post-vaccination with V116 and PCV15 (a pneumococcal conjugate vaccine that includes 15 serotypes) + PPSV23 (comprised of the polysaccharides from 23 of the serotypes causing disease in adults) post-vaccination within each vaccination group separately.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL V116
- BIOLOGICAL PPSV23
- BIOLOGICAL PCV15
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 518 participants |
| Start Date | 2023-02-13 |
| Est. Completion | 2024-02-16 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05696080
The ClinicalTrials.gov registry entry for NCT05696080 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 518 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT05696080 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05696080 about?
NCT05696080 is a clinical study titled "Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008)". The primary objectives of this study are to evaluate the safety and tolerability of the pneumococcal 21 valent conjugate vaccine (V116), and to evaluate the serotype-specific opsonophagocytic activity (OPA) post-vaccination with V116 and PCV15 (a pneumococcal conjugate vaccine that includes 15 serot...
What is the current status of trial NCT05696080?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 518 participants. The study started on 2023-02-13. Estimated completion is 2024-02-16.
What interventions are being tested in trial NCT05696080?
The interventions under investigation include: Placebo (BIOLOGICAL), V116 (BIOLOGICAL), PPSV23 (BIOLOGICAL), PCV15 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05696080?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.